F-star Shares Rise On Bispecific Antibody Therapeutics Pact With Janssen

Loading...
Loading...
  • F-star Therapeutics Ltd FSTX has entered into a license and collaboration agreement with Janssen Biotech Inc, a unit of Johnson & Johnson JNJ.
  • Under the terms of the agreement, F-star will grant Janssen a worldwide, exclusive royalty-bearing license to research, develop, and commercialize up to five bispecific antibodies directed to Janssen therapeutic targets using F-star's Fcab and mAb2 platforms. 
  • Janssen will be responsible for all research, development, and commercialization activities under the agreement.
  • Under the terms of the agreement, F-star is entitled to receive upfront fees of $17.5 million, near-term fees, and potential further milestones of up to $1.35 billion. 
  • F-star is also eligible to receive potential tiered mid-single digit royalties on annual net sales.
  • Related: F-star's FS118 Development Program To Include Checkpoint Naïve Cancer Patients.
  • Price Action: FSTX shares are up 9.53% at $7.01 during the premarket session on the last check Wednesday.
Posted In: BiotechLong IdeasNewsHealth CareContractsMoversTrading IdeasGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!

Loading...